AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaPRNewsWire • 06/28/24
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular LymphomaPRNewsWire • 06/26/24
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for June 2024InvestorPlace • 06/20/24
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of DirectorsPRNewsWire • 06/20/24